The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×3•Originally published 23 April 2026•Updated 24 April 2026•

1 min read

FDA Approves Regeneron Gene Therapy for Rare Genetic Deafness

Key Facts

1The U.S. Food and Drug Administration approved Regeneron's gene therapy for a rare genetic form of deafness.

Regeneron has secured FDA approval for its gene therapy Otarmeni, targeting OTOF-related hearing loss, following a record-breaking 61-day priority review process. This accelerated approval via a pilot program underscores the therapy's clinical significance, supported by CHORD trial data showing 42% of participants achieved full hearing restoration. The treatment is administered through a specialized syringe and catheter kit, with reported side effects including ear infections, nausea, and dizziness. In a strategic move to ensure patient access, Regeneron will provide the therapy free of charge to eligible individuals within the United States. While the free-access initiative may impact immediate financials, the rapid regulatory milestone reinforces Regeneron's leadership in the precision medicine sector. Investors are now focused on the long-term commercial scalability of this genetic research platform.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: Added details regarding the record 61-day approval timeline, the FDA priority pilot program, clinical side effects, and the specific administration method.

Version 2about 1 month ago

What changed: Added scientific name lunsotogene parvec-cwha, identified OTOF as the genetic target, and included the 80% success rate from the CHORD trial.

Version 1about 1 month ago

What changed: Added the brand name (Otarmeni), the accelerated approval pathway details, the 42% clinical success rate, and the company's announcement of a free-access program for U.S. patients.